• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    2/8/23 11:51:55 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    SC 13G/A 1 hsica5_20823.htm LONGVIEW PARTNERS (GUERNSEY) LIMITED hsica5_20823.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 5)*
    Henry Schein, Inc.
    (Name of Issuer)
    Common Stock
    (Title of Class of Securities)
    US8064071025
    (CUSIP Number)
    December 31, 2022
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: US8064071025
           
    1
    NAME OF REPORTING PERSON
    Longview Partners (Guernsey) Limited
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Channel Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    3,669,916
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    7,015,011
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    7,015,011
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.18%
    12
    TYPE OF REPORTING PERSON
    KC & IA
    CUSIP No.: US8064071025
           
    1
    NAME OF REPORTING PERSON
    Longview Partners LLP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United Kingdom
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    3,669,916
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    7,015,011
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    7,015,011
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.18%
    12
    TYPE OF REPORTING PERSON
    IA & PN
    CUSIP No.: US8064071025
           
    1
    NAME OF REPORTING PERSON
    Longview Partners (UK) Limited
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    United Kingdom
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    3,669,916
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    7,015,011
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    7,015,011
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.18%
    12
    TYPE OF REPORTING PERSON
    HC
    CUSIP No.: US8064071025
    ITEM 1(a). NAME OF ISSUER:
    Henry Schein, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    135 Duryea Road
    Melville, NY 11747
    ITEM 2(a). NAME OF PERSON FILING:
    Longview Partners (Guernsey) Limited
    Longview Partners LLP
    Longview Partners (UK) Limited
    (Collectively referred to hereafter as "Longview Partners")
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    Longview Partners (Guernsey) Limited
    PO Box 559
    Mill Court
    La Charroterie
    St Peter Port
    Guernsey
    GY1 6JG

    Longview Partners (UK) Limited and Longview Partners LLP are both located at:
    SavoyStrand
    105 Strand
    London WC2R 0AA
    ITEM 2(c). CITIZENSHIP:
    Longview Partners (Guernsey) Limited is a Guernsey registered company
    Longview Partners LLP is a UK limited liability partnership
    Longview Partners (UK) Limited is a UK registered company
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock
    ITEM 2(e). CUSIP NUMBER:
    US8064071025
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [X]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    Longview Partners (Guernsey) Limited is an investment advisor registered under section 203 of the Investment Advisors Act of 1940.

    Longview Partners (UK) Limited is 100% owned by Longview Partners (Guernsey) Limited.

    Longview Partners (UK) Limited is the managing member of Longview Partners LLP.
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    7,015,011
    (b) Percent of class:
    5.18%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    Longview Partners (Guernsey) Limited :

    Longview Partners LLP :

    Longview Partners (UK) Limited :
    (ii) shared power to vote or to direct the vote:
    Longview Partners (Guernsey) Limited : 3,669,916

    Longview Partners LLP : 3,669,916

    Longview Partners (UK) Limited : 3,669,916
    (iii) sole power to dispose or direct the disposition of:
    Longview Partners (Guernsey) Limited :

    Longview Partners LLP :

    Longview Partners (UK) Limited :
    (iv) shared power to dispose or to direct the disposition of:
    Longview Partners (Guernsey) Limited : 7,015,011

    Longview Partners LLP : 7,015,011

    Longview Partners (UK) Limited : 7,015,011
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    The shares reported herein have been acquired on behalf of discretionary clients of Longview Partners. Persons other than Longview Partners are entitled to receive dividends from, and proceeds from the sale of, those shares. None of those persons to the knowledge of Longview Partners has an economic interest in more than 5% of the class.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Longview Partners LLP
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    As per Items 2(a) & 3 above
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: US8064071025
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 08 2023
    Longview Partners (Guernsey) Limited
    By:
    /s/ Stuart J Tostevin
    Name:
    Stuart J Tostevin
    Title:
    Compliance Officer
    February 08 2023
    Longview Partners LLP
    By:
    /s/ Sheila Tickner
    Name:
    Sheila Tickner
    Title:
    Head of Compliance
    February 08 2023
    Longview Partners (UK) Limited
    By:
    /s/ Lucy-Ellen Berwick
    Name:
    Lucy-Ellen Berwick
    Title:
    Company Secretary
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $HSIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    2/26/2024$78.00Market Perform
    Leerink Partners
    12/12/2023$71.00 → $82.00Neutral → Overweight
    JP Morgan
    11/10/2023$70.00Hold → Buy
    Stifel
    8/8/2022$80.00Sell → Neutral
    UBS
    More analyst ratings

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Henry Schein to Participate in Upcoming Investor Conferences in May

      Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conferences in May: Bank of America Healthcare Conference at the Encore Hotel in Las Vegas on May 14, 2025, at 10:00 a.m. Pacific time (1:00 p.m. Eastern time). Stifel Jaws & Paws Conference at Lotte Hotel, New York City, on May 29, 2025, at 12:40 p.m. Eastern time. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc

      5/6/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Reports First Quarter 2025 Financial Results

      First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

      5/5/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Medical Announces Winner of Its 2025 Rising Star Award

      Fifth Annual Award Spotlights Up-and-Coming Athletic Trainers Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (NASDAQ:HSIC), announced today that Ian Jeffer, MS, ATC, LAT, Head Athletic Trainer at Desert Ridge High School in Mesa, Arizona, is the winner of the fifth annual Henry Schein Medical Athletics and Schools Rising Star Award. The recognition celebrates emerging athletic trainers with up to five years of experience in the Sports Medicine industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250418934421/en/From left to right: Ian Jeffer, Marissa Lucas, and Angel Picart. Mr. Jeffer was recognized f

      4/22/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Financials

    Live finance-specific insights

    See more
    • Henry Schein Reports First Quarter 2025 Financial Results

      First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

      5/5/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on

      4/8/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Detailed 2025 Financial Guidance

      Fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19 Fourth-quarter 2024 operating cash flow of $204 million; full-year 2024 operating cash flow of $848 million, up $348 million compared with 2023 2025 non-GAAP diluted EPS expected to be in the range of $4.80 to $4.94 with mid-single digit 2025 Adjusted EBITDA growth Announces new reportable segments to provide more meaningful information for investors Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter and full year ended December 28, 2024. The financial result

      2/25/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Lin Max claimed no ownership of stock in the company (SEC Form 3)

      3 - HENRY SCHEIN INC (0001000228) (Issuer)

      5/8/25 4:10:36 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Director Laskawy Philip A sold $184,999 worth of shares (2,604 units at $71.04), decreasing direct ownership by 10% to 24,805 units (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      3/20/25 4:28:08 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • EVP & Chief Operating Officer Ettinger Michael S gifted 455 shares, decreasing direct ownership by 0.44% to 103,693 units (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      3/20/25 4:24:09 PM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      11/13/24 3:30:01 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Henry Schein Inc.

      SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

      11/12/24 9:32:27 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      2/14/24 11:18:57 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Henry Schein Inc.

      SCHEDULE 13D/A - HENRY SCHEIN INC (0001000228) (Subject)

      5/6/25 4:15:28 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Henry Schein Inc.

      10-Q - HENRY SCHEIN INC (0001000228) (Filer)

      5/5/25 1:41:33 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HENRY SCHEIN INC (0001000228) (Filer)

      5/5/25 6:14:20 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Henry Schein with a new price target

      Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00

      2/14/25 7:05:26 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein upgraded by BofA Securities with a new price target

      BofA Securities upgraded Henry Schein from Underperform to Buy and set a new price target of $84.00 from $69.00 previously

      1/6/25 8:12:21 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Mizuho initiated coverage on Henry Schein with a new price target

      Mizuho initiated coverage of Henry Schein with a rating of Neutral and set a new price target of $75.00

      12/4/24 7:41:29 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Give Kids A Smile Program Celebrates 23rd Year of Providing Free Oral Health Care Services to Underserved Children

      The American Dental Association Foundation's Initiative, with Exclusive National Sponsors Henry Schein and Colgate-Palmolive, Continues to Expand Its Reach, With Nearly 325,500 Children Expected to Receive Care Throughout 2025 The American Dental Association Foundation (ADA Foundation) is celebrating the 23rd year of its Give Kids A Smile® (GKAS) program, which officially launched on Friday, February 7, at the 2025 national kick-off event at Meharry Medical College School of Dentistry. Since its national launch in 2003, GKAS volunteers have provided free oral health education and services to more than 9.5 million underserved children in the U.S. This press release features multimedia. Vi

      2/10/25 6:30:00 AM ET
      $CL
      $HSIC
      Package Goods/Cosmetics
      Consumer Discretionary
      Medical Specialities
      Health Care